BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37772799)

  • 1. A rapid HPV typing assay to support global cervical cancer screening and risk-based management: A cross-sectional study.
    Inturrisi F; de Sanjosé S; Desai KT; Dagnall C; Egemen D; Befano B; Rodriguez AC; Jeronimo JA; Zuna RE; Hoffman A; Farhat Nozzari S; Walker JL; Perkins RB; Wentzensen N; Palefsky JM; Schiffman M
    Int J Cancer; 2024 Jan; 154(2):241-250. PubMed ID: 37772799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redesign of a rapid, low-cost HPV typing assay to support risk-based cervical screening and management.
    Desai KT; Adepiti CA; Schiffman M; Egemen D; Gage JC; Wentzensen N; de Sanjose S; Burk RD; Ajenifuja KO
    Int J Cancer; 2022 Oct; 151(7):1142-1149. PubMed ID: 35666530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
    Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
    Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
    [No Abstract]   [Full Text] [Related]  

  • 6. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
    Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
    BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: A retrospective study of 8726 cases.
    Tao X; Zhang H; Zhang H; Xiao Y; Zhong F; Zhou X; Cong Q; Sui L; Zhao C
    Cancer Cytopathol; 2022 Jul; 130(7):542-550. PubMed ID: 35312217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Performance of human papillomavirus typing test in cervical precancer lesions and cervical cancer screening].
    Zhang SK; Luo XP; Li ZF; Su Z; Xia JC; Hu GY; Zhu YJ; Xie LX; Feng XX; Sun XB; Chen W; Qiao YL
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):252-256. PubMed ID: 32252206
    [No Abstract]   [Full Text] [Related]  

  • 9. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
    Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
    Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing.
    Demarco M; Carter-Pokras O; Hyun N; Castle PE; He X; Dallal CM; Chen J; Gage JC; Befano B; Fetterman B; Lorey T; Poitras N; Raine-Bennett TR; Wentzensen N; Schiffman M
    J Clin Microbiol; 2018 May; 56(5):. PubMed ID: 29491018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
    Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
    Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.
    Oštrbenk Valenčak A; Šterbenc A; Seme K; Poljak M
    J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31666369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the ScreenFire and Xpert HPV assays for the detection of human papillomavirus and cervical precancer among women living with HIV in Malawi.
    Mungo C; Guliam A; Chinula L; Inturrisi F; Msowoya L; Mkochi T; Jawadu S; de Sanjosé S; Schiffman M; Tang JH; Smith JS
    medRxiv; 2024 Feb; ():. PubMed ID: 38617305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results.
    Schiffman M; Burk RD; Boyle S; Raine-Bennett T; Katki HA; Gage JC; Wentzensen N; Kornegay JR; Aldrich C; Tam T; Erlich H; Apple R; Befano B; Castle PE
    J Clin Microbiol; 2015 Jan; 53(1):52-9. PubMed ID: 25339396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Influence of Human Papillomavirus Genotypes on Visual Screening and Diagnosis of Cervical Precancer and Cancer.
    Jeronimo J; Bansil P; Valdez M; Kang LN; Zhao FH; Qiao YL; Chen W; Zhang X; Paul P; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
    J Low Genit Tract Dis; 2015 Jul; 19(3):220-3. PubMed ID: 25279978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk stratification of type-specific human papillomavirus for cervical precancers: evidence from a cross-sectional study in Shenzhen].
    Liu ZH; Lin W; Wang YY; Wu B; Yuan SX; Yao JL; Zhao XS; Chen B; Qiao YL; Zhao FH; Chen W; Hu SY
    Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):757-763. PubMed ID: 30392340
    [No Abstract]   [Full Text] [Related]  

  • 17. Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology.
    Stoler MH; Wright TC; Parvu V; Yanson K; Cooper CK; Andrews J
    Gynecol Oncol; 2019 Apr; 153(1):26-33. PubMed ID: 30638767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants.
    Wang SS; Zuna RE; Wentzensen N; Dunn ST; Sherman ME; Gold MA; Schiffman M; Wacholder S; Allen RA; Block I; Downing K; Jeronimo J; Carreon JD; Safaeian M; Brown D; Walker JL
    Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):113-20. PubMed ID: 19124488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
    Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
    Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
    Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
    J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.